These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 39401968)
21. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. Colunga A; Pulliam T; Nghiem P Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527 [TBL] [Abstract][Full Text] [Related]
24. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma. Bénigni P; Guénolé M; Bonsang B; Marcorelles P; Schick U; Uguen A Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):17-22. PubMed ID: 31343994 [TBL] [Abstract][Full Text] [Related]
25. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Feldmeyer L; Hudgens CW; Ray-Lyons G; Nagarajan P; Aung PP; Curry JL; Torres-Cabala CA; Mino B; Rodriguez-Canales J; Reuben A; Chen PL; Ko JS; Billings SD; Bassett RL; Wistuba II; Cooper ZA; Prieto VG; Wargo JA; Tetzlaff MT Clin Cancer Res; 2016 Nov; 22(22):5553-5563. PubMed ID: 27166398 [TBL] [Abstract][Full Text] [Related]
26. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications. Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167 [TBL] [Abstract][Full Text] [Related]
27. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options. Gehrcken L; Sauerer T; Schaft N; Dörrie J Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385 [TBL] [Abstract][Full Text] [Related]
28. Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma. Pulliam T; Jani S; Jing L; Ryu H; Jojic A; Shasha C; Zhang J; Kulikauskas R; Church C; Garnett-Benson C; Gooley T; Chapuis A; Paulson K; Smith KN; Pardoll DM; Newell EW; Koelle DM; Topalian SL; Nghiem P Cell Rep Med; 2024 Feb; 5(2):101412. PubMed ID: 38340723 [TBL] [Abstract][Full Text] [Related]
29. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists. Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ Front Immunol; 2024; 15():1334769. PubMed ID: 38312842 [TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma. Guénolé M; Bénigni P; Bourbonne V; Lucia F; Legoupil D; Pradier O; Misery L; Uguen A; Schick U J Cancer Res Clin Oncol; 2021 Sep; 147(9):2569-2578. PubMed ID: 34115240 [TBL] [Abstract][Full Text] [Related]
31. Merkel Cell Polyomavirus Infection Induces an Antiviral Innate Immune Response in Human Dermal Fibroblasts. Krump NA; Wang R; Liu W; Yang JF; Ma T; You J J Virol; 2021 Jun; 95(13):e0221120. PubMed ID: 33883226 [TBL] [Abstract][Full Text] [Related]
32. Association of Merkel Cell Polyomavirus Status With p53, RB1, and PD-L1 Expression and Patient Prognosis in Merkel Cell Carcinomas: Clinical, Morphologic, and Immunohistochemical Evaluation of 17 Cases. Öğüt B; Bayram EK; İnan MA; Kestel S; Erdem Ö Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):371-378. PubMed ID: 37126387 [TBL] [Abstract][Full Text] [Related]
33. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Vandeven N; Nghiem P Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685 [TBL] [Abstract][Full Text] [Related]
34. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma. Wardhani LO; Matsushita M; Iwasaki T; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K Hum Pathol; 2019 Feb; 84():52-61. PubMed ID: 30240768 [TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. Samimi M Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027 [TBL] [Abstract][Full Text] [Related]
37. Characterization of the Impact of Merkel Cell Polyomavirus-Induced Interferon Signaling on Viral Infection. Wang R; Yang JF; Senay TE; Liu W; You J J Virol; 2023 Apr; 97(4):e0190722. PubMed ID: 36946735 [TBL] [Abstract][Full Text] [Related]